Biotech

All Articles

Neurocrine's KarXT competitor reaches in phase 2-- yet just at reduced dose

.Neurocrine Biosciences has actually attained its hoped-for account in a phase 2 schizophrenia trial...

Vaderis' uncommon blood vessel problem medicine decreases nosebleeds

.Vaderis Therapeutics' target to build the 1st medicine aimed specifically at a specific unusual cap...

Navigator raises $100M to cultivate brand-new autoimmune pipeline

.Navigator Medicines has furnished on its own along with $one hundred million in collection A funds ...

Duality looks for cash money for ADC tests as IPO wave spreads to Asia

.China's Duplicity Biotherapeutics has submitted (PDF) documentation for a Hong Kong IPO, looking fo...

YolTech offers China civil rights to genetics editing therapy for $29M

.4 months after Chinese genetics modifying business YolTech Therapeutics took its cholesterol levels...

Addex inventory increases after Indivior provides to $300M for substance

.Indivior is picking up a little molecule allosteric modulator designed to alleviate substance use a...

Molecular Allies adjusts AML test over 'suboptimal exposure'

.Molecular Partners has determined "suboptimal exposure" to its own tetra-specific T-cell engager as...